Ian E. Krop
About
Ian E. Krop is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research.
According to data from OpenAlex, Ian E. Krop has authored 298 papers receiving a total of 19.0k indexed citations (citations by other indexed papers that have themselves been cited), including 255 papers in Oncology, 138 papers in Pulmonary and Respiratory Medicine and 94 papers in Cancer Research. Recurrent topics in Ian E. Krop's work include HER2/EGFR in Cancer Research (173 papers), Cancer Treatment and Pharmacology (114 papers) and Advanced Breast Cancer Therapies (87 papers). Ian E. Krop is often cited by papers focused on HER2/EGFR in Cancer Research (173 papers), Cancer Treatment and Pharmacology (114 papers) and Advanced Breast Cancer Therapies (87 papers). Ian E. Krop collaborates with scholars based in United States, Spain and France. Ian E. Krop's co-authors include Eric P. Winer, Véronique Dièras, David Miles, Manfred Welslau, Sunil Verma, Ellie Guardino, Mark D. Pegram, Luca Gianni, Kim T. Blackwell and Michael W. Lu and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.
In The Last Decade
Ian E. Krop
288 papers receiving 18.7k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ian E. Krop United States | 68 | 13.9k | 5.7k | 5.4k | 4.7k | 4.0k | 298 | 19.0k | ||
| Mark D. Pegram United States | 56 | 17.8k 1.3× | 8.5k 1.5× | 4.6k 0.8× | 6.8k 1.4× | 4.9k 1.2× | 221 | 23.8k | ||
| Francisco J. Esteva United States | 68 | 11.6k 0.8× | 4.9k 0.9× | 3.2k 0.6× | 7.0k 1.5× | 4.6k 1.2× | 280 | 18.0k | ||
| Véronique Dièras France | 63 | 18.5k 1.3× | 3.1k 0.5× | 9.5k 1.7× | 4.3k 0.9× | 6.3k 1.6× | 354 | 23.3k | ||
| Mario Campone France | 66 | 15.3k 1.1× | 3.2k 0.6× | 9.0k 1.7× | 7.6k 1.6× | 7.1k 1.8× | 538 | 23.9k | ||
| Sara M. Tolaney United States | 54 | 11.6k 0.8× | 2.0k 0.4× | 5.3k 1.0× | 2.8k 0.6× | 3.7k 0.9× | 502 | 14.8k | ||
| William Novotny United States | 38 | 12.5k 0.9× | 2.6k 0.5× | 5.7k 1.0× | 8.0k 1.7× | 3.8k 0.9× | 110 | 22.6k | ||
| Virginia Paton United States | 19 | 9.9k 0.7× | 4.6k 0.8× | 2.6k 0.5× | 3.5k 0.7× | 2.6k 0.7× | 31 | 13.3k | ||
| Steven Wong United States | 17 | 11.5k 0.8× | 6.6k 1.2× | 2.0k 0.4× | 6.6k 1.4× | 3.0k 0.8× | 36 | 16.0k | ||
| Wendy J. Levin United States | 14 | 11.5k 0.8× | 6.6k 1.2× | 2.0k 0.4× | 6.5k 1.4× | 2.8k 0.7× | 36 | 15.8k | ||
| Lyndsay N. Harris United States | 53 | 9.3k 0.7× | 3.0k 0.5× | 2.9k 0.5× | 5.1k 1.1× | 5.5k 1.4× | 192 | 15.0k |
Countries citing papers authored by Ian E. Krop
Since
Specialization
Citations
This map shows the geographic impact of Ian E. Krop's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ian E. Krop with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ian E. Krop more than expected).
Fields of papers citing papers by Ian E. Krop
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Ian E. Krop. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ian E. Krop. The network helps show where Ian E. Krop may publish in the future.
Co-authorship network of co-authors of Ian E. Krop
This figure shows the co-authorship network connecting the top 25 collaborators of Ian E. Krop. A scholar is included among the top collaborators of Ian E. Krop based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ian E. Krop. Ian E. Krop is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Fehm, Tanja, Francesco Cottone, Fabrice André, et al.. (2024). Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial. The Lancet Oncology. 25(5). 614–625.
2.
Lipsyc-Sharf, Marla, Esha Jain, Laura C. Collins, et al.. (2023). Genomics of ERBB2-Positive Breast Cancer in Young Women Before and After Exposure to Chemotherapy Plus Trastuzumab. JCO Precision Oncology. 7(7). e2300076–e2300076.
3.
Saura, Cristina, Shanu Modi, Ian E. Krop, et al.. (2023). Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01). Annals of Oncology. 35(3). 302–307.
4.
Weiss, Anna, Qingchun Jin, Adrienne G. Waks, et al.. (2023). Axillary Nodal Response to Neoadjuvant T-DM1 Combined with Pertuzumab in a Prospective Phase II Multi-Institution Clinical Trial. Journal of the American College of Surgeons. 238(3). 303–311.
5.
Lipsyc-Sharf, Marla, Elza C. de Bruin, Robert McEwen, et al.. (2022). Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer. Journal of Clinical Oncology. 40(22). 2408–2419.
6.
Parsons, Heather A., Erin Macrae, Hao Guo, et al.. (2021). Phase II Single-Arm Study to Assess Trastuzumab and Vinorelbine in Advanced Breast Cancer Patients With HER2-Negative Tumors and HER2-Positive Circulating Tumor Cells. JCO Precision Oncology. 5(5). 896–903.
7.
Vaz-Luís, Inês, Tianyu Li, Nabihah Tayob, et al.. (2021). A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer. Breast Cancer Research and Treatment. 189(2). 411–423.
8.
Tsurutani, Junji, Hiroji Iwata, Ian E. Krop, et al.. (2020). Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors. Cancer Discovery. 10(5). 688–701.
9.
Dièras, Véronique, David Miles, Sunil Verma, et al.. (2017). Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. The Lancet Oncology. 18(6). 732–742.
10.
Lee, Helen, Anthony F. Shields, Barry A. Siegel, et al.. (2017). 64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer. Clinical Cancer Research. 23(15). 4190–4202.
11.
Lin, Nancy U., Hao Guo, Jeffrey T. Yap, et al.. (2015). Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003). Journal of Clinical Oncology. 33(24). 2623–2631.
12.
Cheng, Hailing, Carolynn E. Ohlson, Elaine Xu, et al.. (2015). PIK3CAH1047R- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling. Oncogene. 35(23). 2961–2970.
13.
Dièras, Véronique, Nadia Harbeck, G. Thomas Budd, et al.. (2014). Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: An Integrated Safety Analysis. Journal of Clinical Oncology. 32(25). 2750–2757.
14.
Tolaney, Sara M., Howard A. Burris, Elaina M. Gartner, et al.. (2014). Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer. Breast Cancer Research and Treatment. 149(1). 151–161.
15.
Giordano, Sharon H., Sarah Temin, Jeffrey J. Kirshner, et al.. (2014). Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology. 32(19). 2078–2099.
16.
Vaz-Luís, Inês, Davinia Seah, Erin M. Olson, et al.. (2013). Clinicopathological Features Among Patients With Advanced Human Epidermal Growth Factor–2-Positive Breast Cancer With Prolonged Clinical Benefit to First-Line Trastuzumab-Based Therapy: A Retrospective Cohort Study. Clinical Breast Cancer. 13(4). 254–263.
17.
Schott, Anne F., Melissa D. Landis, Gabriela Dontu, et al.. (2013). Preclinical and Clinical Studies of Gamma Secretase Inhibitors with Docetaxel on Human Breast Tumors. Clinical Cancer Research. 19(6). 1512–1524.
18.
Krop, Ian E., Patricia LoRusso, Kathy D. Miller, et al.. (2012). A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine. Journal of Clinical Oncology. 30(26). 3234–3241.
19.
Beeram, Muralidhar, Ian E. Krop, Howard A. Burris, et al.. (2012). A phase 1 study of weekly dosing of trastuzumab emtansine (T‐DM1) in patients with advanced human epidermal growth factor 2–positive breast cancer. Cancer. 118(23). 5733–5740.
20.
Pettersson, Filippa, Christina Yau, Biljana Culjkovic‐Kraljacic, et al.. (2011). Ribavirin Treatment Effects on Breast Cancers Overexpressing eIF4E, a Biomarker with Prognostic Specificity for Luminal B-Type Breast Cancer. Clinical Cancer Research. 17(9). 2874–2884.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Mark D. Pegram Breakdown of academic impact, for papers by Francisco J. Esteva Breakdown of academic impact, for papers by Véronique Dièras Breakdown of academic impact, for papers by Mario Campone Breakdown of academic impact, for papers by Sara M. Tolaney Breakdown of academic impact, for papers by William Novotny Breakdown of academic impact, for papers by Virginia Paton Breakdown of academic impact, for papers by Steven Wong Breakdown of academic impact, for papers by Wendy J. Levin Breakdown of academic impact, for papers by Lyndsay N. Harris